RxDoctor Payments Data

Peter Drolet, PA

Physician Assistant · Little Rock, ARNPI 1922704055

Payments from drug & device makers

$1,049in general payments, 2019–2025

Across 16 payments — averaging $65.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$267
  • Abiomed$240
  • Abbott$203
  • Johnson & Johnson$118
  • Lexicon Pharmaceuticals, Inc.$113
  • Pfizer$63
  • plus $44 from 2 others
$148in research payments, 2019–2025

Across 1 payment — averaging $148.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$148

What the payments were for

  • Food & beverage$1,049100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,049 in reported general payments places this provider in the 65th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$49,854
Medicare patients
295
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$68,445
XareltoRivaroxaban35$21,340
BrilintaTicagrelor37$18,630
EntrestoSacubitril/Valsartan18$14,720
Prasugrel Hcl50$5,602
ClopidogrelClopidogrel Bisulfate258$2,588
Bumetanide29$1,302
Potassium Chloride97$1,133
Atorvastatin Calcium120$1,072
Colchicine16$670
Isosorbide Mononitrate ErIsosorbide Mononitrate50$439
Metoprolol Succinate54$408
Furosemide84$382
Pantoprazole Sodium28$342
Amiodarone Hcl18$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$68,44585 claims
Johnson & JohnsonXarelto$118$21,34035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →